Faculty Investigator Nick Cochran, PhD, focuses his research efforts on genomic approaches for the diagnosis and treatment of Alzheimer’s disease and related dementias. He and his lab aim to better understand genetic changes that contribute to the development and progression of neurodegenerative diseases, as well as those that may increase an individual’s risk of disease.

The lab uses basic biology techniques, genetic association studies, and genome-wide functional genomics approaches to identify new gene candidates and risk variants in relevant genes involved in Alzheimer’s disease.

The lab currently focuses its efforts on the following areas:

  • Identifying new genes and genetic variants associated with neurodegenerative diseases or related phenotypes
  • Determining the mechanism of regulation of genes associated with neurodegenerative diseases or related phenotypes
  • Applying genome-wide approaches to assess the interaction between genetic variation and neurodegeneration-associated phenotypes

Recent News

January 16, 2024
A research team from HudsonAlpha identified 97 candidate regulatory elements that control the expression of MAPT, a major gene involved in neurodegenerative diseases.
March 23, 2023
The results of the largest study to date looking at genetic modifiers of the age of onset of dementia were recently published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association. Cochran, along with collaborators...
September 1, 2021
HudsonAlpha is investing in its neurogenomics research through the addition of faculty investigator Nick Cochran, PhD. If his name sounds familiar, that is because Cochran was most recently a senior postdoctoral scientist in the l...
Load More